Glowing Plants Firm Gets Venture Backing

After raising more than $450,000 on Kickstarter, a startup making glow-in-the-dark houseplants attracts seed funding from a Silicon Valley venture capital firm.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Arabidopsis thaliana, ine of the plants Glowing Plant seeks to light upWIKIMEDIA, SUI-SETZPlants genetically modified to glow in the dark just got one step closer to becoming a household reality. Glowing Plant, a fledgling synthetic biology company that intends to sell Arabidopsis thaliana and rose seeds that will grow glowing plants, has been backed by Y Combinator, a Silicon Valley venture capital firm that makes small investments in a large number of startups every year. Glowing Plant made more than $450,000 last year with a campaign on Kickstarter. The move marks an incursion into the life science space for Y Combinator, which has thus far invested in web and tech companies rather than in biotechs.

Glowing Plant’s CEO Antony Evans told TechCrunch that Y Combinator saw a viable investment in his company in part due to plummeting costs surrounding genome sequencing and gene manipulation technologies. “The rise of the affordable biotech company is what’s driving [Y Combinator’s] interest in the space,” he said. “Costs are coming down tremendously fast.”

In the midst of its Kickstarter campaign, Glowing Plant was criticized by environmental groups that opposed the project due to a perceived lack of regulatory oversight.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies